BioCryst Pharmaceuticals (NASDAQ:BCRX) Coverage Initiated at Wedbush

Wedbush assumed coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report released on Tuesday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $15.00 price target on the biotechnology company’s stock. Wedbush’s target price would suggest a potential upside of 80.94% from the stock’s previous close.

A number of other equities research analysts have also issued reports on BCRX. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Barclays boosted their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Evercore ISI raised their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $15.43.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $8.29 on Tuesday. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $9.50. The company has a 50 day moving average price of $8.03 and a 200 day moving average price of $7.84. The stock has a market capitalization of $1.72 billion, a P/E ratio of -13.59 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $130.05 million. The firm’s quarterly revenue was up 40.8% on a year-over-year basis. During the same period last year, the business posted $0.28 EPS. On average, research analysts forecast that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BCRX. Mackenzie Financial Corp grew its holdings in shares of BioCryst Pharmaceuticals by 190.7% during the fourth quarter. Mackenzie Financial Corp now owns 84,662 shares of the biotechnology company’s stock worth $637,000 after buying an additional 55,535 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $33,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of BioCryst Pharmaceuticals by 3.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company’s stock valued at $3,016,000 after purchasing an additional 11,581 shares during the last quarter. Woodline Partners LP acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $3,385,000. Finally, Two Sigma Advisers LP increased its holdings in shares of BioCryst Pharmaceuticals by 14.6% in the fourth quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company’s stock valued at $18,799,000 after purchasing an additional 318,800 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.